中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 36 Issue 2
Feb.  2020
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2020  >  36(2): 377-380

Construction of the eukaryotic expression vector of collagen triple helix repeat containing 1 gene and its association with microRNA-30b

DOI: 10.3969/j.issn.1001-5256.2020.02.029

  • Graduate School of Hebei Medical University

Research funding:

 

  • Received Date: 2019-08-15
  • Published Date: 2020-02-20
    Abstract

  • Objective To construct pCTHRC1-IRES2-EGFP eukaryotic expression vector,and to investigate the association between collagen triple helix repeat containing 1( CTHRC1) gene and miR-30 b. Methods Specific primers were designed and PCR was used for the amplification and synthesis of the sequence of CTHRC1 CDS + 3 'UTR region,which was then cloned into the pIRES2-EGFP eukaryotic expression vector to obtain the p CTHRC1-IRES2-EGFP eukaryotic expression vector. Nhe I/Xho I double enzyme electrophoresis and sequencing were used for identification,and the lipofection method was used to evaluate the transfection efficiency of Huh7 and HepG2 cells.After miR-30 b mimic,control,p CTHRC1-IRES2-EGFP plasmid,and pIRES2-EGFP plasmid were transfected into 293 T cells,Western Blot and quantitative real-time PCR were used to measure the protein expression of CTHRC1 and the expression of miR-30 b at 48 hours after transfection. The association between CTHRC1 gene and miR-30 b was analyzed. The independent samples t-test was used for comparison between two groups. Results Nhe I/Xho I double enzyme digestion was performed for the p CTHRC1-IRES2-EGFP eukaryotic expression vector,and two fragments with a length of 5300 bp and 1100 bp were obtained,which was consistent with the expected results;the sequencing results also showed that the sequence was exactly the same as that published in GeneBank,suggesting that the pCTHRC1-IRES2-EGFP eukaryotic expression vector was constructed successfully. In the transfection of Huh7 and HepG2 cells,2 μg p CTHRC1-IRES2-EGFP plasmid had a transfection efficiency of 90% and 89%,respectively,while 4 μg p CTHRC1-IRES2-EGFP plasmid had a transfection efficiency of 85% and 83%,respectively. In 293 T cells,the expression of CTHRC1 decreased to the miR-30 b group( P <0. 05). The expression of miR-30 b decreased in the group with overexpressed CTHRC1( P < 0. 05). Conclusion The eukaryotic expression vector of pCTHRC1-IRES2-EGFP is successfully constructed,and the expression of CTHRC1 is negatively correlated with the expression of miR-30 b in 293 T cells.

     

    • FullText(HTML)
    • References(20)
  • [1] LI L,HU Z. MiR-155-5p modulates malignant behaviors of hepatocellular carcinoma by directly targeting CTHRC1 and indirectly regulating GSK-3β-involved Wnt/β-catenin signaling[J]. Transplantation,2018,102(5):312.
    [2] ZHENG M,ZHOU Q,LIU X,et al. CTHRC1 overexpression promotes cervical carcinoma progression by activating the Wnt/PCP signaling pathway[J]. Oncol Rep,2019,41(3):1531-1538.
    [3] LI N,CHEN L,LIU C,et al. Elevated CTHRC1 expression is an indicator for poor prognosis and lymph node metastasis in cervical squamous cell carcinoma[J]. Hum Pathol,2019,85:235-241.
    [4] LIU Y,ABULIMITI N,WANG C. Collagen triple helix repeat containing 1 expression in osteosarcoma:A new predictor of prognosis[J]. Ann Clin Lab Sci,2018,48(3):338-344.
    [5] QUINTAVALLE C,DONNARUMMA E,IABONI M,et al. Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells[J]. Oncogene,2013,32(34):4001-4008.
    [6] GAZIEL-SOVRAN A,SEGURA MF,DI MICCO R,et al. miR-30b/30d regulation of Gal NAc transferases enhances invasion and immunosuppression during metastasis[J]. Cancer Cell,2011,20(1):104-118.
    [7] HOU M,CHENG Z,SHEN H,et al. High expression of CTHRC1promotes EMT of epithelial ovarian cancer(EOC)and is associated with poor prognosis[J]. Oncotarget,2015,6(34):35813-35829.
    [8] WANG P,WANG YC,CHEN XY,et al. CTHRC1 is upregulated by promoter demethylation and transforming growth factor-beta1 and may be associated with metastasis in human gastric cancer[J]. Cancer Sci,2012,103(7):1327-1333.
    [9] TAN F,LIU F,LIU H,et al. CTHRC1 is associated with peritoneal carcinomatosis in colorectal cancer:A new predictor for prognosis[J]. Med Oncol,2013,30(1):473.
    [10] PARK EH,KIM S,JO JY,et al. Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells[J]. Carcinogenesis,2013,34(3):694-702.
    [11] LAI YH,CHEN J,WANG XP,et al. Collagen triple helix repeat containing-1 negatively regulated by microRNA-30c promotes cell proliferation and metastasis and indicates poor prognosis in breast cancer[J]. J Exp Clin Cancer Res,2017,36(1):92.
    [12] QIN X,CHEN J,WU L,et al. MiR-30b-5p acts as a tumor suppressor,repressing cell proliferation and cell cycle in human hepatocellular carcinoma[J]. Biomed Pharmacother,2017,89:742-750.
    [13] CHEN S,LI P,YANG R,et al. microRNA-30b inhibits cell invasion and migration through targeting collagen triple helix repeat containing 1 in non-small cell lung cancer[J]. Cancer Cell Int,2015,15:85.
    [14] LIAO WT,YE YP,ZHANG NJ,et al. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS,PIK3CD and BCL2[J]. J Pathol,2014,232(4):415-427.
    [15] ZHU ED,LI N,LI BS,et al. miR-30b,down-regulated in gastric cancer, promotes apoptosis and suppresses tumor growth by targeting plasminogen activator inhibitor-1[J].PLo S One,2014,9(8):e106049.
    [16] LI Q,ZHANG X,LI N,et al. miR-30b inhibits cancer cell growth,migration,and invasion by targeting homeobox A1 in esophageal cancer[J]. Biochem Biophys Res Commun,2017,485(2):506-512.
    [17] ICHIKAWA T,SATO F,TERASAWA K,et al. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells[J]. PLo S One,2012,7(2):e31422.
    [18] LI L,WANG B. Overexpression of microRNA-30b improves adenovirus-mediated p53 cancer gene therapy for laryngeal carcinoma[J]. Int J Mol Sci,2014,15(11):19729-19740.
    [19] ZHANG D,LIU Z,ZHENG N,et al. MiR-30b-5p modulates glioma cell proliferation by direct targeting MTDH[J]. Saudi J Biol Sci,2018,25(5):947-952.
    [20] ZHOU X,HUANG L. DNA transfection mediated by cationic liposomes containing lipopolylysine:Characterization and mechanism of action[J]. Biochim Biophys Acta,1994,1189(2):195-203.
    • Relative Articles

  • Relative Articles

    [1]Ke SHI, Qun ZHANG, Xianbo WANG, Ying FENG. Effect of intestinal flora and metabolites on the development and progression of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2025, 41(3): 568-573. doi: 10.12449/JCH250327
    [2]Viral Hepatitis Group of Professional Committee of Liver Disease （combined traditional Chinese and western medicine） of Chinese Research Hospital Association, Zhejiang Provincial Key Laboratory for Accurate Diagnosis and Treatment of Chronic Liver Diseases. Guidelines for fecal microbiota transplantation therapy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2025, 41(3): 424-431. doi: 10.12449/JCH250306
    [3]Xiaoming WU, Qiang HE, Linyi HOU, Yan HU, Xiaofang ZHEN, Jing HAO, Yan SHENG. Effect of Yudantong decoction on intestinal flora and intestinal barrier function in mice with cholestasis induced by α-naphthyl isothiocyanate[J]. Journal of Clinical Hepatology, 2023, 39(4): 864-875. doi: 10.3969/j.issn.1001-5256.2023.04.018
    [4]Hongkai XU, Chunfu WANG, Ye ZHANG, Jianqi LIAN. Role of fecal microbiota transplantation in chronic liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(9): 2237-2243. doi: 10.3969/j.issn.1001-5256.2023.09.031
    [5]Guirong CHEN, Minggang WANG, Huaming LIN, Huiping YAN, Xiufeng WANG. Changes and pathogenic mechanism of intestinal flora in acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(8): 1992-1998. doi: 10.3969/j.issn.1001-5256.2023.08.034
    [6]Quan ZHOU, Chunlin CAI, Jinqiang LI. Gut-liver axis： Intestinal microbial homeostasis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2710-2717. doi: 10.3969/j.issn.1001-5256.2023.11.029
    [7]Yixin HOU, Qun ZHANG, Yuyong JIANG, Hao YU, Yuying YANG, Xianbo WANG. Effect of Liangxue Jiedu decoction on intestinal flora in patients with hepatitis B virus-related acute-on-chronic liver failure: An analysis based on high-throughput sequencing[J]. Journal of Clinical Hepatology, 2022, 38(6): 1280-1287. doi: 10.3969/j.issn.1001-5256.2022.06.013
    [8]Fuchun WANG, Ziyi LI, Wanjie ZHANG, Xiaorong MAO, Junfeng LI. The significance of gut microbiota in acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(7): 1667-1670. doi: 10.3969/j.issn.1001-5256.2022.07.040
    [9]Transplantation Immunology Committee of Branch of Organ Transplantation Physician of Chinese Medical Doctor Association, Organ Transplant Rehabilitation Committee of China Association Rehabilitation Medicine, Branch of Organ Transplantation Physician of Guangdong Medical Doctor Association. Expert consensus on liver transplantation perioperative evaluation and rehabilitation for acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(12): 2701-2708. doi: 10.3969/j.issn.1001-5256.2022.12.005
    [10]Hui DENG, Bin ZHANG, Bin ZHU, Zhayier DILIHUMAER, Weixian WANG, Chunxia GUO, Dongliang YANG, Xin ZHENG, Junzhong WANG, Baoju WANG. Research advances in the role of gut microbiota in chronic hepatitis B, chronic hepatitis C, and related liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(5): 1143-1147. doi: 10.3969/j.issn.1001-5256.2022.05.035
    [11]Mingyin MAN, Nana LI, Yue BU, Kaijiang YU. Influence of mitochondria-targeted antioxidant SS-31 on acute liver injury in a mouse model of sepsis[J]. Journal of Clinical Hepatology, 2022, 38(2): 392-396. doi: 10.3969/j.issn.1001-5256.2022.02.025
    [12]Xujuan LUO, Xue BAI, Zenghui LI, Fan LIU, Hao TANG, Ruoxin LI, Guodong YANG. Clinical effect of fecal microbiota transplantation versus the traditional Chinese medicine Rheum officinale in a rat model of hyperlipidemic acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(12): 2767-2773. doi: 10.3969/j.issn.1001-5256.2022.12.016
    [13]Ziwei GUO, Jiaxin ZHANG, Shuo LI, Xiaobin LI, Shun ZHU, Qian JIN, Xiaoke LI, Yongan YE. Research advances in intestinal flora and the development and prognosis of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2022, 38(5): 1137-1142. doi: 10.3969/j.issn.1001-5256.2022.05.034
    [14]Lingyan XIAO, Awen XING, Shanzhong TAN. Research advances in the association between liver failure and intestinal barrier injury[J]. Journal of Clinical Hepatology, 2021, 37(11): 2710-2714. doi: 10.3969/j.issn.1001-5256.2021.11.049
    [15]Yanyan CHEN, Yanmei LAN, Minggang WANG, Dewen. MAO. Mechanism of action of bile acid-farnesoid X receptor-intestinal microecological axis in the development of liver failure and liver regeneration[J]. Journal of Clinical Hepatology, 2021, 37(2): 480-484. doi: 10.3969/j.issn.1001-5256.2021.02.049
    [16]Menghao LI, Kai LI, Shihao TANG, Zhengyu WANG, Wengang GUO, Zhanxin YIN, Guohong HAN. Changes in gut microbiota after transjugular intrahepatic portosystemic shunt in cirrhotic patients with mild hepatic encephalopathy in different prognosis groups[J]. Journal of Clinical Hepatology, 2021, 37(2): 326-330. doi: 10.3969/j.issn.1001-5256.2021.02.016
    [17]Li HongShan, Hu YiYang. Gut microecology: An important target of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 14-18. doi: 10.3969/j.issn.1001-5256.2020.01.002
    [18]Huang YunYi, Liu Yao, Zhang Qun, Shi Ke, Wang XianBo. Association of intestinal microecology with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2020, 36(4): 912-914. doi: 10.3969/j.issn.1001-5256.2020.04.045
    [19]Huang Qian, Zhang HaiBo, Li JingTao, Wei HaiLiang, Yan ShuGuang, Hui Yi, Chang ZhanJie. Research advances in the mechanism of action of intestinal microecology in intrahepatic cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2355-2359. doi: 10.3969/j.issn.1001-5256.2019.10.050
    [20]Zheng Wei, Zhang YongHong, Zhao Yan. Role of intestinal microflora in the pathogenesis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1613-1615. doi: 10.3969/j.issn.1001-5256.2019.07.041
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(9)

    1. 刘韦，白浪. 慢加急性肝衰竭动物模型研究现状. 临床肝胆病杂志. 2024(01): 187-192 . 本站查看
    2. 陈然，王帅，高扬，杨志琴，徐严. HBV相关慢加急性肝衰竭合并脓毒症的诊疗进展. 肝脏. 2024(07): 867-870 .
    3. 刘扬，洪文，黄克林，杨博，刘亚坡，路明. 粪菌移植对顽固性便秘小鼠的肠道菌群和肠道动力以及TLR4/NF-κB通路蛋白的影响. 现代生物医学进展. 2024(16): 3020-3024 .
    4. 于丹丹，刘亚坡，洪文，杨博，张媛. 粪菌移植对顽固性便秘患者肠道功能、免疫功能及炎症反应的改善效果. 结直肠肛门外科. 2024(05): 578-583 .
    5. 阮浩龙，王宁，于鸿浩，岳鹏鹏. 基于基因编辑技术研究特定基因对小鼠肠道微生物的影响. 中国医学工程. 2024(11): 44-49 .
    6. 徐洪凯，汪春付，张野，连建奇. 粪菌移植在慢性肝病治疗中的应用. 临床肝胆病杂志. 2023(09): 2237-2243 . 本站查看
    7. 周荃，蔡春琳，李金强. 肠-肝轴：肠道微生物稳态与肝细胞癌. 临床肝胆病杂志. 2023(11): 2710-2717 . 本站查看
    8. 周宜，刘晓琴，吴学敏，张浩，王海琴，王红亮，孟祥龙. 乳香及其炮制品对葡聚糖硫酸钠诱导小鼠炎症性肠病的保护作用. 现代药物与临床. 2022(07): 1432-1438 .
    9. 刘蕾，高越颖，郭琳，邱立朋，李会，耿燕. 酒精性肝损伤保护的药理实验教学设计. 实验室研究与探索. 2022(05): 238-243 .

    Other cited types(2)

  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-04051015202530
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 24.6 %FULLTEXT: 24.6 %META: 71.8 %META: 71.8 %PDF: 3.6 %PDF: 3.6 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.4 %其他: 5.4 %其他: 0.9 %其他: 0.9 %Bolivia: 0.1 %Bolivia: 0.1 %Central District: 0.1 %Central District: 0.1 %China: 0.1 %China: 0.1 %Herndon: 0.1 %Herndon: 0.1 %India: 0.1 %India: 0.1 %Malvern: 0.0 %Malvern: 0.0 %Matawan: 0.0 %Matawan: 0.0 %United States: 0.2 %United States: 0.2 %[]: 0.5 %[]: 0.5 %上海: 6.5 %上海: 6.5 %上饶: 0.0 %上饶: 0.0 %东京: 0.1 %东京: 0.1 %东莞: 0.6 %东莞: 0.6 %丽水: 0.0 %丽水: 0.0 %乌鲁木齐: 0.1 %乌鲁木齐: 0.1 %佛山: 0.2 %佛山: 0.2 %佳木斯: 0.0 %佳木斯: 0.0 %保定: 0.1 %保定: 0.1 %六安: 0.0 %六安: 0.0 %兰州: 0.2 %兰州: 0.2 %北京: 4.3 %北京: 4.3 %南京: 1.2 %南京: 1.2 %南宁: 0.4 %南宁: 0.4 %南昌: 0.3 %南昌: 0.3 %南阳: 0.0 %南阳: 0.0 %厦门: 0.0 %厦门: 0.0 %台北: 0.1 %台北: 0.1 %台州: 0.0 %台州: 0.0 %台湾: 0.1 %台湾: 0.1 %台湾省: 0.0 %台湾省: 0.0 %合肥: 0.2 %合肥: 0.2 %吉林: 0.1 %吉林: 0.1 %周口: 0.0 %周口: 0.0 %呼和浩特: 0.1 %呼和浩特: 0.1 %咸阳: 0.0 %咸阳: 0.0 %哈尔滨: 0.1 %哈尔滨: 0.1 %哥伦布: 0.1 %哥伦布: 0.1 %嘉兴: 0.0 %嘉兴: 0.0 %图尔库: 0.0 %图尔库: 0.0 %圣彼得堡: 0.1 %圣彼得堡: 0.1 %大连: 0.1 %大连: 0.1 %大阪: 0.1 %大阪: 0.1 %天津: 0.5 %天津: 0.5 %太原: 0.1 %太原: 0.1 %孝感: 0.2 %孝感: 0.2 %孟买: 0.0 %孟买: 0.0 %宁波: 0.1 %宁波: 0.1 %安康: 0.1 %安康: 0.1 %安顺: 0.1 %安顺: 0.1 %宣城: 0.1 %宣城: 0.1 %密蘇里城: 0.1 %密蘇里城: 0.1 %常德: 0.1 %常德: 0.1 %广州: 1.3 %广州: 1.3 %廊坊: 0.1 %廊坊: 0.1 %弗吉尼亚州: 0.3 %弗吉尼亚州: 0.3 %张家口: 1.2 %张家口: 1.2 %成都: 0.3 %成都: 0.3 %扬州: 0.1 %扬州: 0.1 %新乡: 0.0 %新乡: 0.0 %新德里: 0.0 %新德里: 0.0 %无锡: 0.2 %无锡: 0.2 %昆明: 1.0 %昆明: 1.0 %昌吉: 0.1 %昌吉: 0.1 %晋中: 0.1 %晋中: 0.1 %晋城: 0.1 %晋城: 0.1 %普洱: 0.1 %普洱: 0.1 %曼谷: 0.1 %曼谷: 0.1 %朝阳: 0.2 %朝阳: 0.2 %杭州: 1.0 %杭州: 1.0 %松原: 0.0 %松原: 0.0 %柏林: 0.0 %柏林: 0.0 %柳州: 0.0 %柳州: 0.0 %梧州: 0.0 %梧州: 0.0 %武汉: 1.3 %武汉: 1.3 %汕头: 0.0 %汕头: 0.0 %江门: 0.0 %江门: 0.0 %沈阳: 0.1 %沈阳: 0.1 %法兰克福: 0.0 %法兰克福: 0.0 %法尔肯施泰因: 0.5 %法尔肯施泰因: 0.5 %泰安: 0.0 %泰安: 0.0 %泰州: 0.0 %泰州: 0.0 %洛杉矶: 0.2 %洛杉矶: 0.2 %洛阳: 0.1 %洛阳: 0.1 %济南: 0.1 %济南: 0.1 %海口: 0.1 %海口: 0.1 %海得拉巴: 0.0 %海得拉巴: 0.0 %深圳: 0.6 %深圳: 0.6 %温州: 0.1 %温州: 0.1 %湘潭: 0.0 %湘潭: 0.0 %漯河: 0.0 %漯河: 0.0 %珠海: 0.2 %珠海: 0.2 %石家庄: 0.4 %石家庄: 0.4 %福州: 0.8 %福州: 0.8 %秦皇岛: 0.1 %秦皇岛: 0.1 %米兰: 0.1 %米兰: 0.1 %绍兴: 0.5 %绍兴: 0.5 %绥化: 0.1 %绥化: 0.1 %美国: 0.0 %美国: 0.0 %美国伊利诺斯芝加哥: 0.0 %美国伊利诺斯芝加哥: 0.0 %聊城: 0.0 %聊城: 0.0 %芒廷维尤: 38.9 %芒廷维尤: 38.9 %芝加哥: 0.5 %芝加哥: 0.5 %苏州: 0.3 %苏州: 0.3 %荆州: 0.0 %荆州: 0.0 %莫斯科: 0.8 %莫斯科: 0.8 %衡水: 0.2 %衡水: 0.2 %衢州: 0.0 %衢州: 0.0 %襄阳: 0.0 %襄阳: 0.0 %西宁: 12.9 %西宁: 12.9 %西安: 0.3 %西安: 0.3 %贵阳: 0.1 %贵阳: 0.1 %赤峰: 0.1 %赤峰: 0.1 %辽源: 0.1 %辽源: 0.1 %运城: 0.5 %运城: 0.5 %遵义: 0.0 %遵义: 0.0 %郑州: 2.4 %郑州: 2.4 %重庆: 1.3 %重庆: 1.3 %钦州: 0.1 %钦州: 0.1 %银川: 0.0 %银川: 0.0 %长春: 0.7 %长春: 0.7 %长沙: 1.1 %长沙: 1.1 %长治: 0.1 %长治: 0.1 %防城港: 0.0 %防城港: 0.0 %阿什本: 0.0 %阿什本: 0.0 %青岛: 0.1 %青岛: 0.1 %香港: 0.2 %香港: 0.2 %香港特别行政区: 0.0 %香港特别行政区: 0.0 %驻马店: 0.0 %驻马店: 0.0 %高雄: 0.1 %高雄: 0.1 %黄冈: 0.1 %黄冈: 0.1 %其他其他BoliviaCentral DistrictChinaHerndonIndiaMalvernMatawanUnited States[]上海上饶东京东莞丽水乌鲁木齐佛山佳木斯保定六安兰州北京南京南宁南昌南阳厦门台北台州台湾台湾省合肥吉林周口呼和浩特咸阳哈尔滨哥伦布嘉兴图尔库圣彼得堡大连大阪天津太原孝感孟买宁波安康安顺宣城密蘇里城常德广州廊坊弗吉尼亚州张家口成都扬州新乡新德里无锡昆明昌吉晋中晋城普洱曼谷朝阳杭州松原柏林柳州梧州武汉汕头江门沈阳法兰克福法尔肯施泰因泰安泰州洛杉矶洛阳济南海口海得拉巴深圳温州湘潭漯河珠海石家庄福州秦皇岛米兰绍兴绥化美国美国伊利诺斯芝加哥聊城芒廷维尤芝加哥苏州荆州莫斯科衡水衢州襄阳西宁西安贵阳赤峰辽源运城遵义郑州重庆钦州银川长春长沙长治防城港阿什本青岛香港香港特别行政区驻马店高雄黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (375) PDF downloads(74) Cited by(11)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[3692]YesterdayPV[7162]TodayIP[4969]TodayPV[10545]Online[242]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return